Cancer
Conditions
Keywords
Cancer, Patient Reported Outcomes, Symptom management
Brief summary
A pilot study of an ePRO system in cancer patients receiving systemic therapies.
Detailed description
The primary purpose of this pilot study is to determine the feasibility of the Noona Healthcare Mobile PRO Application to describe oncology patient engagement using a web-based symptom self-monitoring instrument. Additionally, the studyy will dentify side effects as well as long term or chronic adverse events during and following cancer therapy based on the United States (US) National Cancer Institute (NCI) Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE), and identify patients to participate in future long-term Quality of Life studies following cancer therapy. The study is not intended to compare outcomes between groups receiving different therapies.
Interventions
OTHERePRO
Patients will be instructed to log symptoms with an ePRO app using their own personal devices, and prompted once per month for 12 months to log symptoms. These participants will be sent an Adverse Event Questionnaire (AEQ) via the Noona tool that summarizes their symptoms and distress once per month and one week prior to any medically indicated oncology clinic visit. Symptoms designated as clinically severe either during regular symptom logging or via the AEQ will trigger a prompt to contact the clinical team for immediate follow-up. Participants will complete a follow-up questionnaire at 6 months and 12 months following enrollment that includes a self-report of symptom burden, HRQOL, and satisfaction.
Sponsors
Noona Healthcare Inc
Duke University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Individuals (men and women) aged 18 years or older 2. History cancer with no limitation on prior lines of therapy in the metastatic setting 3. ECOG performance status of 0-2 4. Estimated life expectancy of at least 12 months 5. Access to smartphone, tablet or computer with capability to utilize symptom-tracking application 6. Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures 7. Willing and able to comply with all study procedures
Exclusion criteria
1. Concurrent disease or condition that interferes with participation or safety 2. Non-English speaking, as the application is developed in the English language 3. Children will not be included in the study. The pattern of disease and symptoms are different in children than in an adult population. The web-based tool was designed based on the symptom experience of adults with cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Subject participation | 12 months | total number of subjects that participate in the use of a web-based system |
Countries
United States
Outcome results
None listed